Login to Your Account



'Spark' plug: Genable's Rhonova adds inherited retinal disease asset

By Marie Powers
News Editor

Monday, March 7, 2016

Two years after inking an agreement to provide manufacturing services and clinical development assistance for GT038, the lead program at Genable Technologies Ltd., Spark Therapeutics Inc. is acquiring the Dublin-based company and its technology, now known as Rhonova

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription